%PDF-1.4
%
79 0 obj
<>
endobj
76 0 obj
<>
endobj
227 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-11T10:31:24Z
2024-03-28T06:26:51-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T06:26:51-07:00
application/pdf
Heather
2003-532.dec
uuid:1fb140f9-1dd2-11b2-0a00-b50827edca00
uuid:1fb140fc-1dd2-11b2-0a00-380000000000
endstream
endobj
65 0 obj
<>
endobj
66 0 obj
<>
endobj
80 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 53 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
269 0 obj
[274 0 R]
endobj
270 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 55.968 737.5293 Tm
[(16.)-875 (Joseph JE, Harrison P)111 (, Mackie IJ, Isenber)18 (g DA, Machin SJ.)]TJ
2.175 -1.25 Td
(Increased circulating platelet-leukocyte complexes and platelet )Tj
0 -1.25 TD
(activation in patients with antiphospholipid syndrome, systemic)Tj
T*
(lupus erythematosus and rheumatoid arthritis. Br J Haematol)Tj
0 Tc 0 Tw T*
[(2001;1)37 (15:451-9.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Sandor M, L)55 (ynch RG. )18 (The biology and pathology of Fc receptors. )]TJ
2.175 -1.25 Td
(J Clin Immunol 1993;13:237-46.)Tj
-2.175 -1.25 Td
[(18.)-875 (Arnett FC, Edworthy SM, Bloch DA, et al. )18 (The )55 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )55 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )55 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(19.)-875 (Lenkei R, Gratama JW)92 (, Rothe G, et al. Performance of calibration)]TJ
2.175 -1.25 Td
[(standards for antigen quantitation with flow cytometry)65 (. Cytometry)]TJ
0 Tc 0 Tw T*
(1998;33:188-96.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (Bunescu )55 (A, )18 (W)40 (idman J, Lenkei R, Menyes P)111 (, Levin K, Egber)18 (g N.)]TJ
2.175 -1.25 Td
(Increases in circulating levels of monocyte-platelet and )Tj
T*
[(neutrophil-platelet complexes following hip arthroplasty)65 (. Clin Sci)]TJ
0 Tc 0 Tw T*
(2002;102:279-86.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875 (V)111 (eale DJ, Maple C, Kirk G, McLaren M, Belch JJ. Soluble cell)]TJ
2.175 -1.25 Td
(adhesion molecules \321 P-selectin and ICAM-1, and disease activity)Tj
T*
(in patients receiving sulphasalazine for active rheumatoid arthritis.)Tj
T*
(Scand J Rheumatol 1998;27:296-9.)Tj
-2.175 -1.25 Td
[(22.)-875 (Ertenli I, Kiraz S, )55 (Arici M, et al. P-selectin as a circulating )]TJ
2.175 -1.25 Td
(molecular marker in rheumatoid arthritis with thrombocytosis. )Tj
T*
(J Rheumatol 1998;25:1054-8.)Tj
-2.175 -1.25 Td
[(23.)-875 (Littler )55 (AJ, Buckley CD, )18 (W)80 (ordsworth P)111 (, Collins I, Martinson J,)]TJ
2.175 -1.25 Td
[(Simmons DL. )55 (A)-220 (distinct profile of six soluble adhesion molecules)]TJ
T*
[(\(ICAM-1, ICAM-3, )18 (VCAM-1, E-selectin, L-selectin and P-selectin\))]TJ
T*
(in rheumatoid arthritis. Br J Rheumatol 1997;36:164-9.)Tj
-2.175 -1.25 Td
[(24.)-875 (Fijnheer R, Frijns CJM, Korteweg J, et al. )18 (The origin of P-selectin)]TJ
2.175 -1.25 Td
[(as a circulating plasma protein. )18 (Thromb Haemost 1997;77:1081-5.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Blann )55 (AD, Constans J, Carpentier P)111 (, et al. Soluble P)-238 (selectin in )]TJ
2.175 -1.25 Td
[(systemic sclerosis: relationship with von )18 (W)40 (illebrand factor)40 (, )]TJ
T*
[(autoantibodies and dif)18 (fuse or localised/limited disease. )18 (Thromb Res)]TJ
0 Tc 0 Tw T*
(2003;109:203-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Blann )55 (AD, Nadar SK, Lip GY)129 (. )18 (The adhesion molecule P-selectin)]TJ
2.175 -1.25 Td
(and cardiovascular disease. Eur Heart J 2003;24:2166-79.)Tj
-2.175 -1.25 Td
[(27.)-875 (Andre P)111 (, Hartwell D, Hrachovinova I, Saf)18 (faripour S, )18 (W)80 (agner DD.)]TJ
2.175 -1.25 Td
(Pro-coagulant state resulting from high levels of soluble P-selectin)Tj
T*
[(in blood. Proc Natl )55 (Acad Sci USA)-220 (2000;97:13835-40.)]TJ
30.825 47.5 Td
[(28.)-875 (Highton J, Carlisle B, Palmer DG. Changes in the phenotype of)]TJ
2.175 -1.25 Td
[(monocytes/macrophages and expression of cytokine mRNA)-220 (in)]TJ
T*
(peripheral blood and synovial fluid of patients with rheumatoid)Tj
T*
(arthritis. Clin Exp Immunol 1995;102:541-6.)Tj
-2.175 -1.25 Td
[(29.)-875 (T)70 (orsteinsdottir I, )55 (Arvidson NG, H\212llgren R, H\214kansson L.)]TJ
2.175 -1.25 Td
(Monocyte activation in rheumatoid arthritis \(RA\): increased )Tj
T*
(integrin Fc)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.1 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.0249 Tw 5.071 0 Td
[(and complement receptor expression and the ef)18 (fect of)]TJ
-5.071 -1.25 Td
[(glucocorticoids. Clin Exp Immunol 1999;1)37 (15:554-60.)]TJ
-2.175 -1.25 Td
[(30.)-875 (W)80 (atson F)80 (, Robinson JJ, Phelan M, Bucknall RC, Edwards SW)92 (.)]TJ
2.175 -1.25 Td
(Receptor expression in synovial fluid neutrophils from patients)Tj
T*
[(with rheumatoid arthritis. )55 (Ann Rheum Dis 1993;52:354-9.)]TJ
-2.175 -1.25 Td
[(31.)-875 (Quayle JA, )18 (W)80 (atson F)80 (, Bucknall RC, Edwards SW)92 (. Neutrophils from)]TJ
2.175 -1.25 Td
(the synovial fluid of patients with rheumatoid arthritis express the)Tj
T*
[(high af)18 (finity immunoglobulin G receptor)40 (, Fc)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 17.9517 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [-0.1 (RI \(CD64\): role of)]TJ
-17.9517 -1.25 Td
(immune complexes and cytokines in induction of receptor )Tj
T*
(expression. Immunology 1997;91:266-73.)Tj
-2.175 -1.25 Td
[(32.)-875 (Allen E, Bakke )55 (AC, Purtzer MZ, Deodhar )55 (A. Neutrophil CD64)]TJ
2.175 -1.25 Td
(expression: distinguishing acute inflammatory autoimmune disease)Tj
T*
[(from systemic infections. )55 (Ann Rheum Dis 2002;61:522-5.)]TJ
-2.175 -1.25 Td
[(33.)-875 (Felzmann )18 (T)74 (, Gadd S, Majdic O, et al. )55 (Analysis of )]TJ
2.175 -1.25 Td
(function-associated receptor molecules on peripheral blood and)Tj
T*
(synovial fluid granulocytes from patients with rheumatoid and )Tj
T*
[(reactive arthritis. J Clin Immunol 1991;1)37 (1:205-12.)]TJ
-2.175 -1.25 Td
[(34.)-875 (W)80 (einber)18 (g JB, Pippen )55 (AM, Greenber)18 (g CS. Extravascular fibrin )]TJ
2.175 -1.25 Td
(formation and dissolution in synovial tissue of patients with)Tj
T*
[(osteoarthritis and rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:996-1005.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875 (W)80 (allber)18 (g-Jonsson S, Cvetkovic JT)74 (, Sundqvist KG, Lefvert )55 (AK,)]TJ
2.175 -1.25 Td
[(Dahlqvist SR. )55 (Activation of the immune system and inflammatory)]TJ
T*
(activity in relation to markers of atherothrombotic disease and )Tj
T*
(atherosclerosis in rheumatoid arthritis. J Rheumatol )Tj
0 Tc 0 Tw T*
(2002;29:875-82.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875 (W)80 (allber)18 (g-Jonsson S, Rantap\212\212-Dahlqvist S, Nordmark L, R\214nby M.)]TJ
2.175 -1.25 Td
(Mobilization of fibrinolytic enzymes in synovial fluid and plasma)Tj
T*
(of rheumatoid arthritis and spondyloarthropathy and their relation)Tj
T*
(to radiological destruction. J Rheumatol 1996;23:1704-9.)Tj
-2.175 -1.25 Td
[(37.)-875 (McEntegart )55 (A, Capell HA, Creran D, Rumley )55 (A, )18 (W)80 (oodward M,)]TJ
2.175 -1.25 Td
(Lowe GDO. Cardiovascular risk factors, including thrombotic )Tj
T*
(variables, in a population with rheumatoid arthritis. Rheumatology)Tj
0 Tc 0 Tw T*
(2001;40:640-4.)Tj
ET
0 0 0 1 K
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
8 0 0 8 540.968 56.9344 Tm
(2355)Tj
-0.00011 Tc 0.02499 Tw -60.867 -0.1368 Td
(Bunescu, et al: Fc)Tj
/T1_2 1 Tf
0 Tc 0 Tw 8 0 1.7005 8 112.8273 55.8398 Tm
(\002)Tj
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 118.3164 55.8398 Tm
[(r)37 (eceptor and RA)]TJ
ET
0 0 0 0 k
/GS0 gs
101.13 82.75 407.5 -10.83 re
f*
0.5 w
101.13 82.75 407.5 -10.83 re
S
Q
Q
q
1 0 0 1 0 1 cm
0 0 612 792 re
W n
1 0 0 1 0 -1 cm
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_4 8 Tf
112.368 74 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
59 0 obj
<>stream
8;Z\7!E-fh%+G5@kjPb'=Ag'8A\3-@6,[c%f!-5u[NT,=%ft"[#9KMGO22oMn87a'
g._*Hi@WdJc+6'k%[k4^PJ:OJ775G^G,0?4T!m^S?0"cAr?E/"j%gGd#Kb`Ef?%fn
7o_lDaa=l-Gn_'pA4pd+=V771VWko)$/N3k`DmHen..lmI""UNV*_o;F:2]>;U_T+
j\cY4I9L6A/C2*I-u*tXpCKHtF-0a^j@RksW1`j1Wj4]U=,.[Zc>%+\gHWTaY(02-
@H_CR]CIJi\r`h%8F9AF]E*Fb)r"k+B@Iu,B\<1RiT/maAh.oW<6W5A6n5-om-?pM
QJU=U;Z8-$F!B7'ZGr+keWhpZ5^07bf8cW1W[YtT#;lOEA6(<#ANG[kc+mU?#!CWJ
f)kRe*O`7CNBsm[@&B?]]r>
kIg6Vktjn#HZ4*C.Pu;rD4k&qDrs:;YV"U8\f84No>s^ciLkor!]d_[
UGiR_D.>`INe%qOVTWYV<$0=<(G;W7>EiHK?^cWU$O[=M$O[=M56B]WeB?V*n&e:Q
ddo]WQ]c^o64
endstream
endobj
63 0 obj
[/Indexed/DeviceRGB 255 62 0 R]
endobj
62 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
142 0 obj
<>
endobj
98 0 obj
<>
endobj
82 0 obj
<>
endobj
88 0 obj
<>
endobj
123 0 obj
<>
endobj
233 0 obj
<>
endobj
83 0 obj
<>
endobj
114 0 obj
<>stream
H{PSw&ū<.pk}h]j."
ТH!H#!H@!@(Z@`]'UڭNeڞFvt~3g~s93s>?sa8l%6O8y,Mp3r:8'w~2$ WTN89Ff`$SumGO/_^VHRRU삤߰KV~]ήd%lZ˔ƴ$"]HPXvTʾU
RȲ{uJlR$$e s6L&W6!-y\JyD$Y}c`Üb,>0+ưG>=HwO}q>[Ll#FC#IH+J%CoM rcStq?mN{WΘ9ڙ[۟y2w9!-
o{xz| Y\#^熏o=Y>(k֦VE1U2[RYD+Q)?B>F֏vCS,, xKCG,uZ$ )+Z8(nej+sGIh.5+CCTX_(:6xƭ?逥Ѱef5q!O8tA!O A#dvtX,<3SMZmV!\O6/&VP1r@s
ՑuFrta9g;~;봗M9#voĮL>*SrN_~i??
/?,̨DZs;/Y#ۆx5*2cMwGMJڶ FmEfP֍E+Ta aLs@ۉ,V-&~[,1TzJȿB\%yI9jrOD[*SSp"l~veyDV_<®s
EAKڷe7Ufm
33ԨKrOɇL7]'@qa$cP&nsrã8ܿIp6??DyCTZYM76*-*]$66We%JV!ͪm!l>]l弾 U3ngD1E[Wv_
|畱q<ttǧ$kXQLB9R~"G5J(sxN4Kgwg};>zoiK E_ʹL.g5ՠ';[N}%R$9=9l$]jjs=xFu\Z*ˌoZwШWc(׆0+)Ǔϧ\7t5i>5ur}kGPFiU7dq:fQ9yUyE2nݱ
v>U֦])ZhP!bŇA]⠚G
02C$ChC$ϲkn w4{ Xӳ8#([.)mT]3vNq6Q>A